Evidence map›Paper›PMID 32162714›Full record

ArticleThe Prostate2020

Proteomic and transcriptomic profiling of Pten gene-knockout mouse model of prostate cancer.

Jinhui Zhang, Sangyub Kim, Li Li, Christopher J Kemp, Cheng Jiang, Junxuan Lü

Open access · hybridAbstract read
In one paragraph

Article in The Prostate, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.5field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Interception Targets ofCancer prevention research (Philadelphia, Pa.) · 2021
    Article
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Jinhui ZhangDepartment of Biomedical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, Texas.
Sangyub KimDepartment of Pharmacology, Pennsylvania State University College of Medicine, Hershey, Pennsylvania.
Li LiDepartment of Biomedical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, Texas.
Christopher J KempHuman Biology Division and Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Cheng JiangDepartment of Biomedical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, Texas.
Junxuan LüDepartment of Biomedical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, Texas.ORCID 0000-0002-2354-7186
Texas Tech University · USFred Hutch Cancer Center · USPennsylvania State University · US

Funding

PREVENTION OF PROSTATE CARCINOGENESIS BY NEXT-GENERATION SELENIUMR01CA172169 · NCI · TEXAS TECH UNIVERSITY HEALTH SCIS CENTER · PI LU, JUNXUAN · 2013 to 2018
$1.6M
Translational development studies of a novel combination therapy for castration-resistant prostate cancerR21CA218774 · NCI · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI DENG, YIBIN, LU, JUNXUAN · 2018 to 2019
$377k
NCI NIH HHS R01 CA172169NCI NIH HHS R01CA172169NCI NIH HHS R21 CA218774
6 · The paper itself

Abstract

backgroundThe prostate-specific phosphatase and tensin homolog deleted on chromosome 10 (Pten) gene-conditional knockout (KO) mouse carcinogenesis model is highly desirable for studies of prostate cancer biology and chemoprevention due to its close resemblance of primary molecular defect and many histopathological features of human prostate cancer including androgen response and disease progression from prostatic intraepithelial neoplasia to invasive adenocarcinoma. Here, we profiled the proteome and transcriptome of the Pten-KO mouse prostate tumors for global macromolecular expression alterations for signaling changes and biomarker signatures.

methodsFor proteomics, four pairs of whole prostates from tissue-specific conditional knockout Pten-KO mice (12-15 weeks of age) and their respective wild-type littermates housed in the same cages were analyzed by 8-plex isobaric tags for relative and absolute quantitation iTRAQ. For microarray transcriptomic analysis, three additional matched pairs of prostate/tumor specimens from respective mice at 20 to 22 weeks of age were used. Real-time quantitative reverse transcription-polymerase chain reaction was used to verify the trends of protein and RNA expression changes. Gene Set Enrichment Analysis and Ingenuity Pathway Analysis were carried out for bioinformatic characterizations of pathways and networks.

resultsAt the macromolecular level, proteomic and transcriptomic analyses complement and cross-validate to reveal overexpression signatures including inflammation and immune alterations, in particular, neutrophil/myeloid lineage suppressor cell features, chromatin/histones, ion and nutrient transporters, and select glutathione peroxidases and transferases in Pten-KO prostate tumors. Suppressed expression patterns in the Pten-KO prostate tumors included glandular differentiation such as secretory proteins and androgen receptor targets, smooth muscle features, and endoplasmic reticulum stress proteins. Bioinformatic analyses identified immune and inflammation responses as the most profound macromolecular landscape changes, and the predicted key nodal activities through Akt, nuclear factor-kappaB, and P53 in the Pten-KO prostate tumor. Comparison with other genetically modified mouse prostate carcinogenesis models revealed notable molecular distinctions, especially the dominance of immune and inflammation features in the Pten-KO prostate tumors.

conclusionsOur work identified prominent macromolecular signatures and key nodal molecules that help to illuminate the patho- and immunobiology of Pten-loss driven prostate cancer and can facilitate the choice of biomarkers for chemoprevention and interception studies in this clinically relevant mouse prostate cancer model.

Indexed as

AnimalsDisease Models, AnimalGene Expression ProfilingMaleMiceMice, KnockoutOligonucleotide Array Sequence AnalysisProstatic NeoplasmsProteomicsPTEN PhosphohydrolasePTEN PhosphohydrolasePten protein, mouseadenocarcinomaanimal modelexpression signaturesmacromolecular biomarkersprostate cancer

Identifiers

PMID32162714
PMCPMC7187266
OpenAlexW3012529597

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.